Belief BioMed Gains NMPA Clinical Trial Approval for DMD Gene Therapy BBM-D101
China-based gene therapy specialist Belief BioMed Inc. (BBM) has announced that it has received clinical...
Belief BioMed
Belief BioMed and Takeda Win NMPA Approval for China’s First Hemophilia B Gene Therapy
China-based gene therapy specialist Belief BioMed Inc. and Takeda’s (NYSE: TAK, TYO: 4502) China unit...
Belief BioMed’s BBM-D101 Receives FDA Approval for DMD Clinical Trial
China-based gene therapy specialist Belief BioMed Inc. (BBM) has announced receiving clinical trial approval from...
Belief BioMed’s BBM-D101 Receives FDA Orphan Drug and Pediatric Rare Disease Designations for DMD
Belief BioMed has announced that the U.S. Food and Drug Administration (FDA) has granted Orphan...
Belief BioMed Partners with Bayer’s AskBio to Explore New Gene Therapies
Belief BioMed Inc. (BBM), a Chinese biopharmaceutical company specializing in gene therapy, has announced a...
Belief BioMed’s Hemophilia B Gene Therapy BBM-H901 Slated for Priority Review in China
The Center for Drug Evaluation (CDE) has indicated on its website that the market application...
Belief BioMed and Takeda’s Hemophilia B Gene Therapy BBM-H901 Accepted for NMPA Review
Belief BioMed Group (BBM), a Shanghai-based gene therapy specialist, and Takeda have announced that the...
Belief BioMed Group Initiates Clinical Study for Hemophilia A Gene Therapy BBM-H803 in China
Belief BioMed Group, a Shanghai-based gene therapy specialist, has announced the first subject dosing in...
Belief BioMed Partners with Takeda for BBM-H901 Commercialization in Asia
Shanghai-based gene therapy specialist Belief BioMed Group (BBM) has announced a strategic partnership with Japan’s...
Belief BioMed Completes Patient Dosing in Phase III Hemophilia B Gene Therapy Trial
Shanghai-based gene therapy specialist Belief BioMed Group (BBM) has announced the completion of patient dosing...